FMW Media's business TV show, New to The Street, announces signing Acurx Pharmaceuticals, Inc. to an additional six-month media contract for filming and broadcasting tailored interviews, commercials, and digital billboard ads. New to The Street's TV anchors will continue interviewing ACXP's management, discussing and introducing the Company's key business topics. Each filmed interview will air on New to The Street's television syndicated outlets on Newsmax TV and Fox Business Network and as a sponsored program on Bloomberg TV.

Acurx Pharmaceuticals, Inc. is a clinical biopharmaceutical business developing a new class of antibiotics for bacterial infections. The Company's novel Ibezapolstat drug, a potential treatment for Clostridioides difficile infections (CDI), completed FDA clinical results in Phase 1 and 2a and is currently enrolling patients for an FDA Phase 2b clinical trial. CDI kills thousands of people annually, with many catching the infection in hospitals and nursing homes.

Clinical data to date demonstrated that Ibezapolstat eradicated CDI during 3-days of treatment. The New to The Street's social media team and television network partners will re-share media content, creating a platform to increase awareness about Acurx. All broadcasted shows will stream on the New to The Street website,.

On a schedule, show previews and commercial ads will air on selected New to The Street's billboard platform throughout New York City. And New to The Street will provide social media marketing to further the reach of each broadcast airing. TV viewers will learn more about Acurx and get updates as they become available regarding its new class of antibiotics to combat CDI and other bacterial infections.